US Broker Ratings

Amgen Inc. (AMGN) Stock Analysis: Navigating Growth and Stability with a 2.95% Dividend Yield

Amgen Inc. (NASDAQ: AMGN) stands out in the healthcare sector as a global leader in biotechnology, delivering a diverse array of human therapeutics. With a market capitalization of $176.43 billion,..

Danaher Corporation (DHR) Stock Analysis: Evaluating a Strong Buy with 12.51% Upside Potential

Danaher Corporation (NYSE: DHR), a prominent player in the healthcare sector, continues to capture the attention of investors with a market capitalization of $164.98 billion. Operating across Biotechnology, Life Sciences,..

Eli Lilly and Company (LLY) Stock Analysis: Exploring the Robust Growth Potential and Analyst Consensus

Eli Lilly and Company (NYSE: LLY), a stalwart in the healthcare sector, particularly in drug manufacturing, continues to capture investor attention with its impressive financial metrics and growth prospects. With..

Bristol-Myers Squibb (BMY) Stock Analysis: Navigating Potential Upside in Healthcare Giants

Bristol-Myers Squibb Company (NYSE: BMY), a titan in the biopharmaceutical industry, is attracting investor attention with its robust product offerings and promising growth metrics. With a market capitalization of $108.83..

AstraZeneca PLC (AZN) Stock Analysis: A Healthcare Giant with 8% Upside Potential

For investors eyeing the healthcare sector, AstraZeneca PLC (NASDAQ: AZN) presents a compelling opportunity. As a prominent player in the drug manufacturing industry, this UK-based biopharmaceutical titan boasts a market..

Medtronic plc (MDT) Stock Analysis: Navigating a 15.53% Upside Potential in the Dynamic Medical Devices Sector

Medtronic plc (MDT), a titan in the medical devices industry, continues to capture investor interest with its robust portfolio and strategic positioning within the healthcare sector. Headquartered in Galway, Ireland,..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: Navigating Growth with a 7.91% Upside Potential

Thermo Fisher Scientific Inc (NYSE: TMO), a titan in the healthcare sector, particularly within the diagnostics and research industry, continues to capture investor attention with its robust market presence and..

Abivax SA (ABVX) Stock Analysis: A Biotech Powerhouse with 7.75% Potential Upside

Investors with a keen eye for the biotechnology sector may want to turn their attention to Abivax SA (ABVX), a French clinical-stage biotech firm that is making waves with its..

Kamada Ltd. (KMDA) Stock Analysis: Unearthing an 84% Upside Potential in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israeli healthcare company specializing in plasma-derived protein therapeutics, is currently making waves in the drug manufacturing industry with a striking potential upside of 84.14%. For..

AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 50% Upside Potential with Analyst Confidence

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector, is catching the attention of investors, particularly due to its impressive potential upside. With a market capitalization of $529.01..

Autolus Therapeutics plc (AUTL): Analyst Optimism with a 384% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a UK-based biotechnology firm, is gaining attention from investors with a significant potential upside of 384.09%. Specializing in the development of T cell therapies targeting..

COMPASS Pathways (CMPS): Potential 143% Upside as Psilocybin Therapy Nears Key Milestones

COMPASS Pathways Plc – American (CMPS), a trailblazer in the mental health sector, has captured the attention of investors with a compelling upside potential of 143.74%. This UK-based biotechnology firm,..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 155.71% Potential Upside in the Biotech Sector

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) presents an intriguing opportunity within the biotechnology sector, boasting a market capitalization of $796.64 million. As a clinical-stage biopharmaceutical company, Oric is focused on developing..

MeiraGTx Holdings plc (MGTX)

⚠️ No article content returned.

..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Uncovering a 9.22% Potential Upside Amidst Strategic Healthcare Endeavors

Emergent BioSolutions Inc. (NYSE: EBS), a key player in the healthcare sector, specializes in providing critical preparedness and response solutions for various public health threats. With a market cap of..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotechnology Frontier with PROTAC Innovation

Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company, stands at the forefront of pioneering therapies that leverage the body’s natural mechanisms to target and degrade disease-causing proteins. With a market..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 718% Upside in Biotechnology

Investors with an appetite for high-risk, high-reward opportunities might find Humacyte, Inc. (NASDAQ: HUMA) an intriguing candidate. Operating within the biotechnology sector, Humacyte stands out with its innovative approach to..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth

Organogenesis Holdings Inc. (NASDAQ: ORGO), a leader in regenerative medicine, is making waves in the healthcare sector with its advanced wound care and surgical products. As the company continues its..

Prothena Corporation plc (PRTA) Stock Analysis: A Biotech Firm with 112.91% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA) has been drawing considerable attention from investors in the biotechnology sector, thanks to its promising pipeline and a potential upside of 112.91% based on analyst..

EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem with Nearly 98% Upside Potential

Investors seeking high-growth opportunities in the biotechnology sector might find EyePoint, Inc. (NASDAQ: EYPT) particularly compelling. With a focus on developing groundbreaking therapeutics for retinal diseases, EyePoint is positioned at..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds